About Ophthalmic Reconstructive Surgery
Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused during a surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible making patching the area with preserved and processed tissue the only treatment option.
CorNeat KPro
CorNeat EverPatch Design Features
Long-Lasting
Inert and non-degradable material
–
Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response
Ease of
Handling
Extremely easy to handle and suture
-
Elastic and durable (cannot be torn by the sutures)
Safe
Synthetic and therefore cannot transmit disease
–
Biocompatible
–
Thin (100 microns), minimizing risk of dellen
Cost-Effective
Reduces operating time and eye bank costs
-
Eliminates complexities related to the transportation and storage of biological materials
-
Readily available, off-the-shelf, device
-
Substantially longer shelf life than organic/degradable solutions
Aesthetic
Translucent when wet
–
Hardly visible when implanted subconjunctivally
CorNeat EverPatch
The CorNeat EverPatch (scleral patch) is the first synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. It is poised to displace the use of donor and processed tissue, which eventually degrades and carries the risk of disease transmission.
The CorNeat EverPatch is composed of a non-woven, polymer matrix, which integrates with surrounding tissue and is intended to reinforce the sclera and aid the physical reconstruction of the ocular surface.
“The ideal graft material should be long-lasting, sterile, immunologically inactive, cosmetically acceptable, and readily available,” states Seminars in Ophthalmology*. The CorNeat EverPatch was designed with these goals in mind.
*Bains U, Hoguet A. Aqueous Drainage Device Erosion: A Review of Rates, Risks, Prevention, and Repair. Semin Ophthalmol. 2018;33(1):1-10. doi: 10.1080/08820538.2017.1353805. Epub 2017 Dec 6. PMID: 29211548.
Indications
Reinforcing the sclera
Aiding the physical reconstruction of the ocular surface
Regulatory Path
FDA Clearance
As of June 2023, the CorNeat EverPatch was granted FDA 510(k) clearance.
CE Marking
The current plans are geared toward obtaining a CE Marking early in 2025.
The plans above are subject to regulatory approvals and requirements.
For more information about the FIH clinical trial click here, for more information about the additional clinical trial click here.